|
Dec 4
|
Roche joins race for obesity drugs with $2.7 billion Carmot deal
|
|
Dec 4
|
Roche to Buy Carmot Therapeutics for Up to $3.1 Billion in Bet on Obesity Treatments
|
|
Dec 4
|
Roche to Buy Obesity Drug Maker Carmot for $3.1 Billion
|
|
Dec 4
|
Roche joins obesity drug chase with $2.7B deal for startup Carmot
|
|
Dec 4
|
UPDATE 4-Roche joins race for obesity drugs with $2.7 bln Carmot deal
|
|
Dec 4
|
Roche enters into a definitive merger agreement to acquire Carmot Therapeutics, including three clinical stage assets with best-in-class potential in obesity and diabetes
|
|
Nov 28
|
Roivant’s Matt Gline on raising capital and biotech’s outlook for 2024
|
|
Nov 27
|
Roche expands hepatitis diagnostics portfolio to help clinicians diagnose and monitor patients with acute or chronic hepatitis B infection
|
|
Sep 8
|
Alnylam's (ALNY) Zilebesiran Meets Goals in Mid-Stage Study
|
|
Sep 7
|
Roche and Alnylam report positive topline results from Phase 2 study KARDIA-1 of zilebesiran, an investigational RNAi therapeutic in development to treat hypertension in patients at high risk of cardiovascular disease
|
|
Sep 6
|
Roche's (RHHBY) Application for PNH Drug Accepted by FDA
|
|
Sep 6
|
FDA Accepts Application for Genentech’s Crovalimab for the Treatment of PNH, a Rare Life-Threatening Blood Condition
|
|
Sep 5
|
Economist Impact report, Advancing the frontier of health and technology integration: The 2023 Digital Health Barometer highlights opportunities in digitalisation of healthcare
|